Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.995
-0.045 (-2.21%)
Dec 26, 2025, 9:56 AM EST - Market open
Opus Genetics Revenue
Opus Genetics had revenue of $3.08M in the quarter ending September 30, 2025, a decrease of -20.38%. This brings the company's revenue in the last twelve months to $14.63M, up 74.60% year-over-year. In the year 2024, Opus Genetics had annual revenue of $10.99M, down -42.30%.
Revenue (ttm)
$14.63M
Revenue Growth
+74.60%
P/S Ratio
6.92
Revenue / Employee
$812,944
Employees
18
Market Cap
137.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.99M | -8.06M | -42.30% |
| Dec 31, 2023 | 19.05M | -20.80M | -52.20% |
| Dec 31, 2022 | 39.85M | 39.26M | 6,665.70% |
| Dec 31, 2021 | 589.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 75.00K | - | - |
| Dec 31, 2007 | 75.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IRD News
- 9 days ago - Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference - GlobeNewsWire
- 17 days ago - Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease - GlobeNewsWire
- 5 weeks ago - Opus Genetics to Participate in Upcoming Investment Conferences - GlobeNewsWire
- 6 weeks ago - Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease - GlobeNewsWire
- 6 weeks ago - Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Opus Genetics Announces $23 Million Registered Direct Offering - GlobeNewsWire
- 7 weeks ago - Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease - GlobeNewsWire